Telus’s, Regulatory

Telus’s Regulatory Headache Clouds a Quietly Strengthening Balance Sheet

18.06.2026 - 01:13:00 | boerse-global.de

Telus faces CRTC ultimatum on SIM fee and CEO transition. Yet free cash flow rose 19%, debt ratio improved. TELUS Health monetization could re-rate the stock.

Telus Faces CRTC Ultimatum Over SIM Fee Amid CEO Transition and Financial Recovery
Telus’s - Telus’s Regulatory Headache Clouds a Quietly Strengthening Balance Sheet 18.06.2026 - Bild: über boerse-global.de

Telus shares have been sliding for months, and the latest regulatory flare-up is putting fresh pressure on a stock already trading near its 52-week low. The Canadian telecom operator is staring down a deadline from the CRTC to justify a controversial C$15 fee for SIM cards, with the regulator threatening formal legal proceedings if the explanation does not satisfy. At the same time, the company is days away from a leadership transition that could reshape its strategic direction.

The dispute centres on a charge Telus introduced on June 11, 2026 — one day before a nationwide ban on activation fees took effect. The fee applies to all new contracts and standalone purchases, and internal documents show staff have been told they cannot waive it under any circumstances. The CRTC views the charge as a disguised activation fee, arguing that a SIM card (whether physical or digital) is essential for network access. Telus counters that the fee represents the sale of a product, not an administrative charge. The argument becomes harder to sustain with eSIMs, which incur no shipping or inventory costs. Bell and Rogers received similar warning letters, but Telus is the only one facing an immediate ultimatum.

The regulatory pressure arrives at a delicate moment for the company. Long-time chief executive Darren Entwistle is handing the reins to former CIBC boss Victor Dodig on July 1. The CRTC deadline forces the incoming management to act quickly: if Telus fails to deliver a convincing legal rationale, the regulator will launch a formal process that could escalate into fines or mandatory changes to pricing.

Yet beneath the headlines of regulatory conflict, Telus’s underlying financial picture is steadily improving. Net income slumped 52% to C$144 million in the first quarter, but that drop is largely attributable to hefty restructuring costs. Strip out that noise, and free cash flow jumped 19% to C$583 million. Capital expenditure rose to C$651 million, but the company plans to cut spending by 10% for the full year while targeting free cash flow of roughly C$2.45 billion in 2026.

Should investors sell immediately? Or is it worth buying Telus?

The balance sheet is also getting cleaner. The net debt-to-EBITDA ratio fell to 3.5 by the end of March, down from 3.9 a year earlier. Management has set a target of 3.3 for the current year and 3.0 by the end of 2027 — a notable feat for a capital-intensive telecom operator. Meanwhile, the integration of TELUS Digital, which was taken private in October 2025, generated annual cash-flow synergies of C$115 million in the first quarter alone.

A bigger potential catalyst lies in TELUS Health. The division reaches more than 160 million people worldwide, and Telus has hired external financial advisers to explore monetisation options. A successful sale or partnership could turbocharge debt reduction and trigger a re-rating of the stock. The core business is also showing resilience: Telus added 262,000 new mobile and fixed-line contracts in the latest period, pushing total connections up 6% to 17.7 million.

Investors have yet to reward these improvements. The stock, recently at C$16.52, has lost around 8% since the start of the year and sits just above its 52-week low. Technical indicators underline the weakness: the relative strength index reads 33.5, normally a sign of oversold conditions, and the price is more than 3% below its 50-day moving average. The quarterly dividend remains frozen at C$0.4184, which has disappointed income-focused shareholders.

Telus at a turning point? This analysis reveals what investors need to know now.

The market is pricing in plenty of gloom — regulatory risk, a CEO change, and a paused dividend. But the operational and financial trends suggest a business that is quietly healing. Whether that healing is enough to overcome the CRTC’s hammer is the question that will dominate Telus’s week ahead.

Ad

Telus Stock: New Analysis - 18 June

Fresh Telus information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.

Read our updated Telus analysis...

en | CA87971M1032 | TELUS’S | boerse | 69567277 |